Home/Filings/4/0001567619-19-012688
4//SEC Filing

BAUPOST GROUP LLC/MA 4

Accession 0001567619-19-012688

CIK 0001382911other

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 4:57 PM ET

Size

17.1 KB

Accession

0001567619-19-012688

Insider Transaction Report

Form 4
Period: 2019-05-31
Transactions
  • Other

    Warrant Expiring 2020

    2019-05-315,000,0000 total(indirect: See footnote)
    Exercise: $60.00From: 2015-09-10Exp: 2020-09-10Common Stock (500,000 underlying)
  • Other

    Warrant Expiring 2026

    2019-05-31100,000,0000 total(indirect: See footnote)
    Exercise: $15.00From: 2016-09-21Exp: 2026-09-21Common Stock (10,000,000 underlying)
  • Other

    0% Senior Secured Convertible Notes due 2020

    2019-05-310 total(indirect: See footnote)
    Exercise: $7.50From: 2016-09-21Exp: 2020-06-29Common Stock (7,802,197 underlying)
Transactions
  • Other

    0% Senior Secured Convertible Notes due 2020

    2019-05-310 total(indirect: See footnote)
    Exercise: $7.50From: 2016-09-21Exp: 2020-06-29Common Stock (7,802,197 underlying)
  • Other

    Warrant Expiring 2020

    2019-05-315,000,0000 total(indirect: See footnote)
    Exercise: $60.00From: 2015-09-10Exp: 2020-09-10Common Stock (500,000 underlying)
  • Other

    Warrant Expiring 2026

    2019-05-31100,000,0000 total(indirect: See footnote)
    Exercise: $15.00From: 2016-09-21Exp: 2026-09-21Common Stock (10,000,000 underlying)
Transactions
  • Other

    0% Senior Secured Convertible Notes due 2020

    2019-05-310 total(indirect: See footnote)
    Exercise: $7.50From: 2016-09-21Exp: 2020-06-29Common Stock (7,802,197 underlying)
  • Other

    Warrant Expiring 2020

    2019-05-315,000,0000 total(indirect: See footnote)
    Exercise: $60.00From: 2015-09-10Exp: 2020-09-10Common Stock (500,000 underlying)
  • Other

    Warrant Expiring 2026

    2019-05-31100,000,0000 total(indirect: See footnote)
    Exercise: $15.00From: 2016-09-21Exp: 2026-09-21Common Stock (10,000,000 underlying)
Footnotes (4)
  • [F1]This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. ("BG GP"), and Seth A. Klarman (collectively, the "Reporting Persons"). Baupost is a registered investment adviser and acts as an investment adviser to various private investment limited partnerships. BG GP, as the Manager of Baupost, and Seth A. Klarman, as the Managing Member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended, of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships.
  • [F2](Continued from footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purpose of Section 16 or for any other purpose.
  • [F3]Such aggregate principal amount of the 0% Senior Secured Convertible Notes due 2020 ("Notes") were converted into post-petition secured obligations under a debtor-in-possession credit facility entered into on March 12, 2018 and approved by the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") on April 13, 2018. At such time 7,802,197 shares of Common Stock were underlying the remaining outstanding aggregate principal amount of the Notes. On May 31, 2019, the Issuer's Modified Amended Plan of Liquidation (the "Plan of Liquidation"), which was confirmed by the Bankruptcy Court on May 17, 2019, became effective. As provided by the Plan of Liquidation, the Reporting Persons surrendered the Notes in exchange for a pro rata distribution of the Issuer's distributable cash, cash proceeds from tax refunds and unused amounts of wind down reserves, each as defined in the Plan of Liquidation.
  • [F4](Continued from footnote 3)The Plan of Liquidation also provided that all outstanding equity interests would be cancelled for no consideration on the effective date.

Documents

1 file

Issuer

Orexigen Therapeutics, Inc.

CIK 0001382911

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001061768

Filing Metadata

Form type
4
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 4:57 PM ET
Size
17.1 KB